Table 2 The outcome of new drugs.
Total N | Median treatment duration, days (range) | BOR | first-line | second-line | third-line | fourth-line | Total | ||
|---|---|---|---|---|---|---|---|---|---|
Pem | 54 | 87 (1–1301) | CR | 0 | 1 | 0 | 0 | 1 | 19 (35.2%) |
PR | 2 | 6 | 0 | 0 | 8 | ||||
SD | 2 | 7 | 0 | 1 | 10 | ||||
PD | 6 | 19 | 1 | 3 | 29 | 29 (53.7%) | |||
Unknown | 1 | 3 | 1 | 1 | 6 | 6 (11.1%) | |||
Ave | 16 | 99 (0–665) | CR | 0 | 0 | 0 | 0 | 0 | 9 (56.3%) |
PR | 0 | 5 | 0 | 0 | 5 | ||||
SD | 0 | 4 | 0 | 0 | 4 | ||||
PD | 0 | 2 | 1 | 0 | 3 | 3 (18.7%) | |||
Unknown | 0 | 4 | 0 | 0 | 4 | 4 (25.0%) | |||
EV | 11 | 179 (91–611) | CR | 0 | 0 | 0 | 0 | 0 | 10 (90.9%) |
PR | 0 | 1 | 7 | 0 | 8 | ||||
SD | 0 | 0 | 1 | 1 | 2 | ||||
PD | 0 | 0 | 1 | 0 | 1 | 1 (9.1%) | |||
Unknown | 0 | 0 | 0 | 0 | 0 | 0 (0%) | |||
Total | 11 | 52 | 12 | 6 | 81 | ||||
p value | 0.0017 | ||||||||
